Q1 Earnings Forecast for Exelixis Issued By Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Analysts at Leerink Partnrs increased their Q1 2025 earnings per share (EPS) estimates for Exelixis in a report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will post earnings per share of $0.36 for the quarter, up from their previous forecast of $0.35. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Leerink Partnrs also issued estimates for Exelixis’ Q2 2025 earnings at $0.50 EPS, Q4 2025 earnings at $0.68 EPS and FY2025 earnings at $2.15 EPS.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

A number of other research firms have also issued reports on EXEL. Guggenheim reaffirmed a “buy” rating and issued a $42.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. Morgan Stanley upgraded shares of Exelixis from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $30.00 to $40.00 in a research report on Monday, January 27th. Brookline Capital Management started coverage on shares of Exelixis in a research report on Monday, December 23rd. They set a “buy” rating on the stock. BMO Capital Markets cut Exelixis from an “outperform” rating to a “market perform” rating and boosted their price target for the company from $36.00 to $40.00 in a research report on Friday, December 20th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $41.00 price objective on shares of Exelixis in a research report on Thursday, January 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Exelixis currently has a consensus rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Trading Down 0.4 %

Shares of NASDAQ EXEL opened at $36.70 on Friday. The stock has a fifty day simple moving average of $35.71 and a 200-day simple moving average of $33.22. Exelixis has a twelve month low of $20.14 and a twelve month high of $40.02. The stock has a market capitalization of $10.27 billion, a PE ratio of 20.73, a PEG ratio of 1.13 and a beta of 0.57.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB increased its position in Exelixis by 18.1% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 290 shares during the last quarter. Balyasny Asset Management L.P. increased its holdings in shares of Exelixis by 1.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock worth $573,000 after buying an additional 317 shares during the last quarter. Steward Partners Investment Advisory LLC raised its position in shares of Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after buying an additional 330 shares during the period. Oregon Public Employees Retirement Fund boosted its holdings in Exelixis by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock valued at $1,937,000 after acquiring an additional 354 shares during the last quarter. Finally, Principal Securities Inc. boosted its holdings in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the transaction, the executive vice president now owns 303,310 shares of the company’s stock, valued at $11,216,403.80. This represents a 14.79 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction on Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares of the company’s stock, valued at approximately $13,479,669. This represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.